Annovis Bio Inc. (ANVS): Price and Financial Metrics

Annovis Bio Inc. (ANVS): $11.63

0.57 (-4.67%)

POWR Rating

Component Grades

Momentum

C

Stability

D

Sentiment

Quality

C

ANVS Price/Volume Stats

Current price $11.63 52-week high $22.49
Prev. close $12.20 52-week low $5.42
Day low $11.59 Volume 132,800
Day high $12.20 Avg. volume 268,199
50-day MA $10.34 Dividend yield N/A
200-day MA $10.81 Market Cap 128.06M

ANVS Stock Price Chart Interactive Chart >


Annovis Bio Inc. (ANVS) Company Bio


Annovis Bio, Inc. develops drugs for Alzheimer's and Parkinson's diseases and other neurodegenerative disorders. It offers posiphen compound for mild cognitive impairment and early stage Alzheimer's disease and bisnorcymserine compound that inhibits amyloid formation and prevents the progression of the Alzheimer's disease. The company was founded by Maria Luisa Maccecchini in May 2008 and is headquartered in Berwyn, PA.


ANVS Latest News Stream


Event/Time News Detail
Loading, please wait...

ANVS Latest Social Stream


Loading social stream, please wait...

View Full ANVS Social Stream

Latest ANVS News From Around the Web

Below are the latest news stories about ANNOVIS BIO INC that investors may wish to consider to help them evaluate ANVS as an investment opportunity.

These Stocks under $10 Are Poised To Explode

In this piece, we will take a look at these stocks under $10 are poised to explode. If you want to skip our introduction to these tricky stocks, jump to These 5 Stocks Under $10 Are Poised To Explode. The US equity markets remain on track for a strong finish in 2023 as major indices […]

Yahoo | December 21, 2023

Annovis Bio to Participate in the 139th Yale CEO Summit

BERWYN, Pa., Dec. 11, 2023 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases such as Alzheimer’s (AD) and Parkinson’s disease (PD) today announced its Founder, President and CEO was selected to participate in the 139th Yale CEO Summit in New York on December 11-12, 2023. The Yale CEO Summit is a bi-annual event; it brings together influential CEOs from major US Fortune 500 companies for informal ye

Yahoo | December 11, 2023

Annovis Bio Announces Last Patient Last Visit in the Phase III Study of Buntanetap in Parkinson’s Disease

BERWYN, Pa., Dec. 05, 2023 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases today announced last patient last visit in the phase III study of its lead candidate buntanetap in patients with early Parkinson’s disease (PD). Topline data results are expected in January 2024. "We are pleased to share the completion of our Parkinson's study which marks a significant step forward in our ongoing mission t

Yahoo | December 5, 2023

Annovis Bio (ANVS) Stock Surges 38% in a Month: Here's Why

Annovis' (ANVS) shares surge on the successful development of its lead candidate in Alzheimer's disease.

Yahoo | December 1, 2023

Annovis Bio Appoints Andrew Walsh as Vice President Finance

BERWYN, Pa., Dec. 01, 2023 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases such as Alzheimer’s (AD) and Parkinson’s disease (PD) today announced the appointment of Andrew Walsh as VP, Finance. "We remain steadfast in advancing our lead candidate buntanetap, as we gear up to receive pivotal data from both our Alzheimer’s and Parkinson’s clinical trials in 2024. The addition of Andrew Walsh to our

Yahoo | December 1, 2023

Read More 'ANVS' Stories Here

ANVS Price Returns

1-mo 27.94%
3-mo N/A
6-mo 39.45%
1-year -22.62%
3-year -46.08%
5-year N/A
YTD -37.81%
2023 39.24%
2022 -23.61%
2021 133.16%
2020 N/A
2019 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!